MINUTES OF MEETING - December 6-7 
31 
"ORDA shall inform RAC members of proposed risk 
assessment projects at the same time it seeks 
consultation from the RAC Risk Assessment Sub- 
committee and the NIH Biosafety Committee." 
Dr. Ahmed said that was the sense of his motion. Dr. Gottesman 
accepted this amendment. The RAC then voted on 774/10 as 
published in the Federal Register with Dr. Young's amendment 
and Dr. Barkley's amendment. The vote was seventeen in 
favor, one opposed and no abstentions. Dr. Novick requested 
that he be recorded as voting opposed. 
The text of the motion adopted by the RAC to be added at 
the end of Section I-D of the Guidelines is as follows: 
"Experiments in Categories I-D-l, I-D-2, I-D-3, 
I-D-5, and experiments involving 'wild-type' 
host-vector systems are excepted from the pro- 
hibitions, provided that these experiments are 
designed for risk assessment purposes and are 
conducted within the NIH high-containment 
facilities located in Building 41-T on the 
Bethesda campus and in Building 550 located at 
the Fredrick Cancer Research Center. The selec- 
tion of laboratory practices and containment 
equipment for such experiments shall be approved 
by ORDA following consultation with the RAC 
Risk-Assessment Subcommittee and the NIH Bio- 
safety Committee. ORDA shall inform RAC members 
of the proposed risk-assessment projects at the 
same time it seeks consultation from the RAC 
Risk-Assessment Subcommittee and the NIH Bio- 
safety Committee. If a major biohazard is 
determined, the clones will be destroyed after 
the completion of the experiment rather than 
retaining them in the high containment facility. 
Other clones that are non-hazardous or not of 
major hazard will be retained in the high 
containment." 
C. Proposed amendment to permit use of CPC Class 3 agents. 
Dr. Talbot noted that this item (767) had not appeared in the 
Federal Register prior to the meeting and cannot be formally 
[ 424 ] 
